Zhengzhou University
Clinical trials sponsored by Zhengzhou University, explained in plain language.
-
New drug cocktail aims to beat rare lymphoma without chemo
Disease control Not yet recruitingThis study tests whether a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) can effectively treat marginal zone lymphoma in people who have not received prior therapy. About 50 adults aged 18-75 with advanced disease will take the drugs and be monitored regu…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 03, 2026 21:34 UTC
-
New hope for brain cancer: CAR-T plus stem cell combo targets hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests a new treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two targeted drugs (orelabrutinib and sintilimab) to see if it can control the disease better. The study will inc…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC